Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Cancer Gene Therapy|November 21, 1998
Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanomaJ Nemunaitis, C Bohart, T Fong, et al.
Joint Commission Journal on Quality and Patient Safety|July 28, 2022
The Kaiser Permanente Northern California Advance Alert Monitor Program: An Automated Early Warning System for Adults at Risk for In-Hospital Clinical DeteriorationVanessa A Martinez, Robin K Betts, Elizabeth A Scruth, et al.
Antimicrobial Agents and Chemotherapy|October 30, 2013
A small-molecule inhibitor of hepatitis C virus infectivityCaroline O Bush, Maria V Pokrovskii, Roland Saito, et al.
Practical Radiation Oncology|January 17, 2017
Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancerH D Heerkens, W A Hall, X A Li, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2024
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinomaT Enzler, A Nguyen, J Misleh, et al.
Practical Radiation Oncology|August 25, 2024
Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment VolumesSara E Beltran Ponce, Christina J Small, Talha Ahmad, et al.
Practical Radiation Oncology|February 11, 2018
Pancreatic gross tumor volume contouring on computed tomography (CT) compared with magnetic resonance imaging (MRI): Results of an international contouring conferenceWilliam A Hall, Hanne D Heerkens, Eric S Paulson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2019
Feasibility and accuracy of quantitative imaging on a 1.5 T MR-linear acceleratorErnst S Kooreman, Petra J van Houdt, Marlies E Nowee, et al.
ESMO Open|February 13, 2026
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trialT Macarulla, R Pazo Cid, M S Womack, et al.
ESMO Open|August 5, 2025
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trialD Melisi, T Macarulla, C De La Fouchardière, et al.
Pageof 12